Q3 2023 ANI Pharmaceuticals Inc Earnings Call
Please standby we're about to begin.
Good day, everyone and welcome to the anti Pharmaceuticals, Inc. Third quarter 2023 earnings results call.
At this time all participants are in a listen only mode.
Later, you will have the opportunity to ask a question. During the question and answer session. You may registered to ask a question at any time by pressing star one on your telephone keypad.
Find out your question has been answered you may remove yourself by pressing star two.
Please note this call is being recorded.
I'll be standing by should you need any assistance and if in any audio assistance is needed you May press star zero.
At this time it is my pleasure to turn the conference over to Judy Diclemente with Investor Relations for Eni. Please go ahead.
Thank you Jamie.
Welcome to anti Pharmaceuticals third quarter 2023 earnings results call. This is Judy diclemente of insight Communications Investor Relations for Eni.
With me on today's call are Nicole Ahwahnee, President and Chief Executive Officer, and Stephen Curry Chief Financial Officer.
You can also access the webcast of this call through the investors section of the a and I website at Www Dot Eni Pharmaceuticals Dot com.
Before we get started I would like to remind everyone that any statements made on today's conference call that express a belief expectation projection forecast anticipation or intent regarding future events and the company's future performance may be considered forward looking statements as defined by the private securities.
Litigation Reform Act.
These forward looking statements are based on information available to and I Pharmaceuticals management as of today and involve risks and uncertainties, including those noted in our press release issued this morning, and our filings with the SEC.
Such forward looking statements are not guarantees of future performance actual results may differ materially from those projected in the forward looking statements.
And I, specifically disclaims any intent or obligation to update these forward looking statements, except as required by law.
Archived webcast will be available for 30 days on our website and I pharmaceuticals Dot com.
For the benefit of those who may be listening to the replay or archived webcast. This call was held and recorded on November eight 2023.
Since then and I may have made announcements related to the topics discussed. So please reference the company's most recent press releases and our SEC filings and with that I'll turn the call over to Nick kill all wanting to kill.
Thank you Judy.
Good morning, everyone and thank you for joining the Eni Pharmaceuticals third quarter earnings call and Thank you for your next question Eni Pharmaceuticals.
First I would like to express tremendous gratitude to our customers suppliers and investors for their strong support of our.
My team and our board as we worked tirelessly to fulfill our purpose.
Certain patients.
Improving lives.
Our time tested values.
Teamwork innovation integrity compliance.
<unk> ability.
Mr Excellence and always putting the patient first digest everyday as we keep striving for.
Jody Tusa.
<unk> lives.
Turning now to our business performance for the third quarter Steve.
Stephen I will share the details of our financial results.
We've built across key business segments, and our overall confidence in the company's ability to drive sustainable profitable growth.
I'm delighted to share the clarity of strategy and very strong execution has enabled to eni delivered another record quarter for revenue and adjusted non-GAAP EBITDA.
This record quarterly performance also allowed us to raise full year 2020 guidance for the third quarter in a row.
This morning, we reported record net quarterly revenues of $131 8 million an.
An increase of 57% over the third quarter of 2022 and up 13% over the record we achieved last quarter.
Equally impressive our adjusted non-GAAP EBITDA was $36 5, million% to 98% year over year increase in our adjusted non-GAAP diluted EPS was $1 27.
Representing a nearly 118% increase over the third quarter of 2022.
These results.
Q4 outlook for all segments have allowed us to once again raise our full year 2023 guidance.
We now expect net revenues to be in the range of $468 million to $478 million.
non-GAAP EBITDA to be between $128 million and $133 million and adjusted non-GAAP earnings per share to be between $4 in 2009 to.
The $4 57.
The midpoint of the revised whole company guidance represents remarkable year over year growth in net revenues of approximately 49% adjusted non-GAAP EBITDA of 133% and adjusted non-GAAP earnings per diluted share of 220.
226%.
Now, let's take a closer look at our performance and the progress progress made against strategic imperatives for our key business segments.
With our rare disease business.
We believe our rare disease business will continue to be the largest driver of eni's.
Future growth.
We will deliver this growth through the purified portrait gel launch momentum is anchored by adding assets that leverage our rare disease infrastructure and capabilities.
Revenues for controls and gel totaled $29 7 million in the third quarter.
An increase of 146% over the prior year and up 22% compared to the second quarter of 2023.
Our Brooklyn gel continues to accelerate with record quarterly new cases initiated a new patient starts.
We also saw increasing momentum with new unique prescribers, including many prescribers, who were naive to ACTH therapy.
The company's efforts to increase the effectiveness of the field sales force and improve awareness of ACTH therapy.
Opiate patients have yielded results.
The outlook for the overall ACTH category remains robust with six consecutive quarters of year over year growth. According to <unk>.
We saw ongoing strength in our targeted specialties of neurology nephrology and rheumatology.
In addition, we made gains to positive response to the company's entry into the Pulmonology specialty.
Also during the quarter, we announced the FDA approval and commercial availability of the new one ml vial size of corporates and Joe.
Only approved purified ACTH indicated for the treatment of acute gouty arthritis flares.
The commercial launch of the one ml vial for acute gouty arthritis flares.
Sorted by Eni's existing sales force.
And while it is still early in the launch we are already receiving positive physician response.
Recently, the company received a specific J code for controls and to support physician administration of the one ml vial.
With momentum from our initial three priority specialties and good progress made with the two new specialties, we are raising our full year revenue guidance for controls and gel $200 million to $107 million.
Up from the previous range of 90 million to $100 million.
The new range represents year over year revenue growth of between 140% at 157% compared to the $42 million recognized in 2022.
As we approach the end of 2023 and move into 2024, our company remains actively committed to increasing the scope and scale of our rare disease portfolio through M&A and in licensing by leveraging our financial strength and the rare disease infrastructure and capabilities that we have built.
Turning now to our generic established brands and other segment.
Which also delivered strong results during the quarter.
<unk> growing by 43% year over year to $102 1 million in the third quarter.
As with the prior two quarters, we were able to leverage the company's operational excellence and U S based manufacturing footprint to fill the gap and pharmaceutical shortages shortages due to supply chain disruptions.
While some of the market opportunities from the past three quarters has softened we remain poised to capitalize on current and future opportunities as an established and reliable partner of choice for our customers.
Our strong R&D organization continued to deliver with five new product launches.
Including Colestipol hydrochloride tablets yesterday, all gel 0.1%.
Alright.
Yeah.
In addition, we filed three new Andas and two new 505, B two applications during the quarter.
We also repaid a number two ranking and competitive generic therapy approvals.
Going forward, our aim for the generics established brands and other segment.
Main focused on driving growth.
Our new product launch execution and operational excellence.
Competitiveness and supply reliability with a patient first orientation.
To support the ongoing growth of this segment. The company has invested in expanding the manufacturing footprint and capacities at the New Jersey site and expect these to be operational by early 2024.
With all that we've put in place during 2023.
Cross all areas of the business.
We are confident in our ability to build a sustainable biopharmaceutical company.
Serving patients.
Improving lives.
And now I'll turn the call over to Steve who will walk through our third quarter financial results and revised guidance in more detail.
Steve.
Okay.
Thank you Nicole and good morning to everyone on the call.
Hum.
That's gonna kill indicated we posted very strong results in third quarter of 2023, we.
We saw growth across our core businesses generating record third quarter revenues of 131 million.
Got it.
This represents $48 million or 57% growth over the $83 8 million reported in the third quarter of 2022.
The 13% sequential increase from the $116 5 million of revenues recorded in the second quarter, which had been the companys previous record.
Revenues from courts Rofin reported in a rare disease segment were 29 7 million in the quarter up 136% from the prior year.
Revenues of our generics established brands and other segment rose $30 9 million to $102 1 million, an increase of 43% over the prior year.
Net revenue gains across the segment reflect the increased volumes on the base business.
Annualized <unk> of 2022 launches and new product launches in 2023.
From a product perspective performance was driven by revenues from year over year gains in products, such as Colestipol Famotidine mixed amphetamine salts extended release Nitro pure employing and thyroid cancer.
Tempered by a decrease in revenues of Fenofibrate Nebivolol and preserves thing among others.
As Nick mentioned earlier, our strong commitment to U S based manufacturing and excellence in generic R&D.
Procurement and sales and marketing.
Enable the Eni to meet market demand for key products in the face of competitive supply chain issues throughout the first three quarters of this year.
The market conditions for specific molecules have changed recently.
As a result, we currently expect fourth quarter established brand revenues to be significantly lower than that that we are reporting this morning for the third quarter of 2023.
We do expect to see ongoing sequential growth in generic revenues. However, it will be tempered by declines in certain molecules.
Importantly, the steps we have taken to enhance the capabilities of Eni has increased our ability to service the supply chain disruptions and our business is well poised to meet current and future opportunities as they arise.
Operating expenses during the third quarter increased by 28% to $113 9 million.
The three months ended September 30th 2023, compared to $88 8 million in the prior year period.
Cost of sales, excluding depreciation and amortization increased by $15 2 million to $48 1 million in the third quarter of 2023.
Compared to $32 9 million in the prior year period.
Given by significant growth in sales volumes.
Eric and rare disease pharmaceutical products.
Research and development expenses were $11 1 million in the third quarter of 2023, an increase of $3 5 million from the prior year period, primarily due to $1 6 million in expenses related to a 505 feet you filing and.
At a higher level of activity associated with ongoing and new projects in the current year period.
Selling general and administrative expenses increased by 40% to 42 million in the third quarter of 2023.
Compared to $30 1 million in the prior year period.
Primarily due to increased employment related costs as well as an overall increase in activity is required to support the significant growth in our business.
Depreciation and amortization expense was $15 2 million for the three months ended September 30th 2023.
An increase of $1 million from the prior year period.
During the quarter, we recognized a gain of $2 6 million.
Arising from the video of the contingent consideration fair value adjustment.
Compared to a loss of $2 5 million in the prior year period.
Primarily due to a change in the anticipated cash flows.
Specifically, extending the timeframe over which cash flows will be generated by the product.
And the passage of time.
As well as an increase to the probability of payment for the product development based milestone payments.
Regarding the closure of our Oakville, Ontario, Canada manufacturing plant.
No P&L impact in the current year period as our restructuring activities are essentially complete.
This is compared to $1 5 million of restructuring expense recorded in the prior year period.
On November six 2023, we entered into an agreement for the sale of the site for a total sales price of 17.85 million Canadian dollars or approximately 13 million U S dollars based on the current exchange rate.
Closing of the sale is currently expected to occur in the first quarter of 2024.
Net income available to common shareholders for the third quarter of 2023 was $9 5 million as compared to a net loss of $9 million in the prior year period.
Diluted GAAP earnings per share was 45 cents as compared.
Two of 55 cents loss in the prior year period.
On an adjusted non-GAAP basis, we had diluted earnings per share of $1 27 for the quarter.
<unk> 258 cents per share in the prior year period.
Adjusted non-GAAP EBITDA for the third quarter of 2023 reached a new company record of $36 5 million and reflects gross profit pull through from the strong revenue performance.
This is an increase of $18 1 million compared to the $18 4 million posted in the prior year period.
Adjusted non-GAAP EBITDA also rose $2 4 million on a sequential basis.
From our previous record $34 1 million recognized in the second quarter of 2023.
From a balance sheet perspective, we ended the quarter with $193 1 million in unrestricted cash.
Driven in part by cash flow from operations of $32 1 million during the quarter ended September 32023.
On a nine month year to date basis, we have generated $74 2 million of cash flow from operations.
We have $294 8 million in face value of outstanding debt.
Which is due in November of 2027.
As of the balance sheet date.
Our gross leverage is two three times and our net leverage is less than one times trailing 12 months adjusted non-GAAP EBITDA of $126 9 million.
Finally, as Kim mentioned and as outlined in this morning's press release, we are pleased to raise full year 2023 guidance as follows.
We are raising total company expected net revenues to be between $468 million and 478 million up from the previously issued guidance of $425 million and 445 million representing <unk>.
Approximately 48% to 51% growth as compared to the $316 4 million recognized for full year 2022.
We are raising total company adjusted non-GAAP EBITDA to be between $128 million and 133 million.
From previously issued guidance of $150 million and $125 million, representing approximately 129% to 138% growth as compared to the $65 9 million recognized in 2022.
We are raising total company adjusted non-GAAP earnings per share to $4 and 29.
The $4.57.
From the previously issued guidance of $3.62 to $4 and 11.
Netting approximately 215% to 236% growth as compared to the one dollar and 36 reported in 2022.
We have raised in courts rofin specific revenue guidance to be in the range of 100 million to $107 million.
Up from previously issued guidance.
Of 90 million to 100 million, representing a 140% to 157% growth as compared to the $41 7 million recognized in 2022.
And we now project total company non-GAAP gross margin to be between 63% and 63, 8%.
As compared to the previously issued guidance of 63% and 64, 8%.
In addition, we currently anticipate between $19 2 million and $19 3 million shares outstanding for purposes of calculating EPS.
In the U S GAAP effective tax rate of between 9% and 13%.
The company will continue to tax effect adjustments for computation of adjusted non-GAAP diluted earnings per share and a tax rate of 24%.
We will now open up the call to questions operator, please announce the instructions.
Thank you ladies and gentlemen at this time, if you would like to ask a question. Please press the star key followed by the one on your telephone keypad.
If you find that your question has been answered you may remove yourself by pressing star kill once again Thats Star one to ask a question and star two to remove yourself well pause for just a moment to simpler question queue.
Okay.
We will take our first question from <unk> Securities.
Good morning. Thank you for taking my questions first wanted to start off on the generics front.
It seems to be there is a shift in tone.
And gravitation towards a little bit of the weakness that youre seeing can you just talk a little bit about that which categories essentially and then a follow up to that is what is the reasoning behind the expansion.
The manufacturing footprint.
Given the softness in the market.
Or maybe it's a little bit exaggerated just to give you a little more color if you can.
Sure.
Good morning lessons. Thank you for your question.
I think first on the on.
On the softness.
Softness is that we've spoken to is with regards to the very specifically to opportunities that arose from.
Specific product level opportunities.
That arose from supply chain disruptions, we remember we had spoken about several structural factors such as product specific issue as manufacturing site related issues arising from FDA audit income outcomes and company specific financial issues.
All of these for our competitors, but that resulted in.
Opportunities for us so when we're talking about softening, where specifically speaking to specific.
Across multiple products across generic and established brands.
Some of these product level opportunities.
The mix of current opportunities.
New opportunities and return of opportunities that have gone away is very dynamic and evolving before.
Before we focus our guidance on sort of overall company numbers right.
Going to your second question, which is.
So the softening again is related to specific supply chain disruption related opportunities that came up.
As Steve mentioned in his remarks, and sort of die that we continue to believe in the growth of the generic business.
The expansion at the New Jersey site is to support that growth and multiyear growth right. So this is it.
The addition of additional capacities in the new Jersey side to support that.
The next two to three years' worth of growth.
Based on products that we have in our portfolio opportunities. So that's new.
Listing products.
Opportunities in our pipeline of new products that we're going to bring to the market. So it is supporting that growth.
Yeah, that's helpful. Perhaps I'll reframe the question in another way.
Are you seeing market weakness or are you seeing more of just the supply chain is essentially kind of resolving and stabilizing.
Yeah. So.
You are seeing.
Specific reserves resolution of <unk>.
Certain supply chain related disruptions, we still think that the.
Macro trends that give rise to the supply chain disruptions, which is the product specific issues. The manufacturing site related issues are company specific financial issues. All of these are persisting so the market macro trend.
Trend is persisting.
Saying that specific opportunities that we had related to these trends are softening some of those are softening.
Is what we're speaking towards yeah. So.
So we're not talking about overall market weakness the weakness at all of course, you heard from many of our competitors in the generic space.
I think you've seen the strength in and what they are reporting so.
I have yes, that's how that is helpful. Thank you.
Okay, just moving on the construction side, so the one milliliter.
Dosage is there a difference in shelf life and would you see a prescribing appealing are prescribing this off label and what essentially is the appeal to prescribers and what's the kind of a potential opportunity for this dosage.
Yeah look the.
Lots of the one ml vial size.
The commercial availability of that is for the adjunctive treatment of certain patients with acute guards Audi arthritis squares.
And recently the company received a specific J code for core program to support physician administration also the one ml a lot. So the one ml vial is for acute gouty arthritis later in certain patients for adjunctive treatment of certain patients with the acute Dr. Dowdy arthritis flares.
While we have received positive initial physician response.
Very early into this launch and we would love to share more.
In the next earnings were asked though as the launch evolves.
Got it okay and just to go back to generics briefly on the three Q results was the impact of loss driven primarily by seasonality you'd say that.
French.
Some sort of perhaps inventory stocking or just product channel mix and then how do you envision essentially given what we discussed earlier are the 24 to kind of shape out. Thank you.
Yes.
I think the generics.
<unk> Q3 performance is driven by a combination of new product launches.
Opportunities from the supply chain disruptions and continued strong performance with our base business. So.
You asked the question on seasonality, we don't believe that from the product portfolio we have.
The seasonality impact.
On that.
And then as far as 2024 goes look we're working through many moving parts and we'll plan on releasing our 2024 financial guidance.
And earnings call, which will occur towards the end of February.
But we continue to as you would have seen even in the R&D expense we continue to.
Invest in R&D for the generics business.
To support the future growth and that growth will come from new product launches.
Cost competitiveness and supply chain reliability.
Thank you Liz.
Got it yeah. Thank you for that Ah Congrats on the quarter again, guys and good luck on the execution.
Thank you Les.
Thank you.
Yeah.
We'll take our next question from send mail Divan with Guggenheim Securities.
Alright, thanks for taking my questions and congrats on the.
Another strong quarter here. So a couple of questions for me first on the consulting side.
You mentioned talked about the one ml I'm curious about the gouty arthritis opportunity in particular, because that is a unique one for you can you maybe just quantify I guess initially any sort of feedback are you know kind of doctor interest in that indication, but also just sort of quantify what you see as a potential opportunity.
That specific indication and then my second question is kind of going back to some of the comments.
Around the sort of softening that youre seeing and I think the main thing is really around 2024.
And I know, you're not going to give guidance until.
And temporary but as I look at things right now based on where you're planning to leave 2023, it looks like the sort of consensus numbers.
Very minimal sales growth for next year.
So it actually sort of below where you would leave this year. So I'm just wondering if you can provide any color at all on how we should think about sort of trajectory for the different businesses for next year at this point understanding that will give more details.
A few months from now, but but it does seem like there's a pretty big disconnect from the trajectory of the business and where consensus numbers are right now for next year.
Hi, good morning, and thank you for your questions.
First your question around.
Like many of our other indications like multiple sclerosis.
Rheumatoid arthritis et cetera, we're focused on patients for whom current treatments are not sufficient.
In the case of gout flares or a patient's acute gouty arthritis flares, there are patients who might benefit from an additional option from the other therapeutics that are available.
We have received positive initial physician response at this.
So far.
It's not something that we can.
We're able to quantify at this point.
And again as we've done consistently.
We try to find a balance between sharing information to assist the investment community and whatnot.
Away competitively sensitive data so please stay tune the mall.
Hum.
We will come back.
On.
To share more about the golf launch.
No that we have assumed no material revenues from gout in the 2023 guidance. So I think that could be a point or two because it's early days in the launch.
And then going back to your question, but to your second question around.
The.
2024.
How that links to the 2023 guidance I mean, yeah bundle, you've been working with us long enough to know that.
We as we've done consistently we deliver what we commit to and this is the continuation of that philosophy.
Being sort of more conservative while giving guidance.
And in terms of 2024.
We do see continued evolution of the BCG launch right.
Ongoing strong execution in our snacks business you also talked about the efforts that we're making to leverage.
BCG launch as well as our anchor.
And core asset in rare disease, and build on that through M&A and in licensing and we've been actively working on that.
As you can see that there are multiple moving parts right, even the supply chain disruptions right.
As I had spoken about there are opportunities that we have.
Had some of them have gone away or new ones that are that are in the bucket. There are current months third persisting. So there are many moving parts.
We're working through the core profit evolution strong cultural fit evolution, the rare disease M&A, the generics growth and the status of the supply chain disruptions and we plan on releasing our 2024 financial guidance as we move forward.
Okay, Alright, Thanks, and then just one quick follow up just again on the sort of commentary around the softening in specific markets, you're seeing what did you say that more on the generic side or more on a tablet brands as anybody is just sort of give us a little bit of directional sense on where you might be seen was the impact.
Sure so.
We are seeing impact across products, both in generics and established brands.
In generics some of the.
Steve mentioned in his remarks that the growth that we're seeing from the other products and the new launches is tempering some of that decline so.
In the Q4 numbers.
You will see the impact more on the established brand side than you will on the generic side.
Okay, Alright thats helpful. Thank you.
Thank you Bob.
We'll take our next question from Oren <unk> with H C Wainwright.
Yeah.
Thanks for taking my questions.
If I could just I guess the approach the same discussion from a little bit different perspective.
Obviously.
Raised guidance dramatically from the beginning of the year from your initial guidance talking about $100 million 90 per cent EPS.
Reyes.
Mostly from the generics.
Yeah.
When you issue guidance.
Yes.
How conservative are you being how are you looking at the world with regards to all these disruptions and opportunities you have do you have to do you have much visibility on these looking forward or do you assume.
The ones that you already have in hand, well.
And.
Shortly.
Forward to be extremely conservative in your guidance I guess.
What I'm asking is you know it is not surprising that some of the opportunities you've experienced this year are rolling off right. They don't last forever, but when you give first time guidance next year or when you had given guidance each quarter. This year. What are you assuming for the durability of those opportunities and do you build and really anything for expected new disk.
Our options to benefit the benefit will come your way.
Thanks.
Sure and good morning, and thank you for your question.
I.
I think we've spoken about this which is that.
When we speak to guidance or wouldn't be giving guidance. We obviously bake in the performance of the previous quarter and then assume.
With the with the many moving parts you know our best understanding of what.
Subset of those opportunities will continue in the subsequent quarter.
Quarters, right and we have some understanding right. If there's a you know a site related issue.
It takes time to resolve those if there's a product level specific technical issue with one player in a five player market. Then you know we know that that could be shortly so we baked in that understanding.
As we're giving guidance and I think too.
You was worse that Steve has used before when he was describing is describing these.
Theres always more in the in the previous.
Period are off the supply chain opportunities from the supply chain, then we assume in the future right.
So our our assumption.
When we were doing were not assuming that these will persist forever and that's why we baked that in as we give guidance and of course as we learn more we try to you know to share that and continue our philosophy of.
And what we will deliver and deliver what we're saying.
Okay, and I think I appreciate you.
If I misheard you you said the biggest quarter over quarter.
Change in Q4 should be on the branded side.
You know, we're not used to seeing the legacy brands aren't used to seeing.
Similar disruptions I guess and the brand side like we do in generics with products coming and going.
Can you comment on whether it would be a tailwind you've had this year have been.
Mostly a volume or a price benefit and expense.
Makes sense, if that's moderating going forward is that due to <unk>.
Pricing dynamics, if it's price is that just the dynamics softening in general whether that's because of payers in contracting et cetera or is it purely a supply and demand issue that's products lead the market to come back prices adjust accordingly.
Yeah, No. That's clear thank you for that question or it's all volume related or you know.
And large portion relates to volume.
It's not driven by pricing.
So I think there's the second part of your question.
Yep.
And can you comment on generic I guess portfolio.
Pricing trends in general I mean, historically, we've gotten commentary from other players about.
Double digit year over year declines or not is that something you can comment across your portfolio.
Yeah.
Much like the larger players and their commentary we have seen some improvement in the in.
And the degree of generic pricing decline.
And yeah, I think that you know.
Versus what it was in past periods, we have seen some improvement. These are not you know.
<unk> separated from the the the macro trend of supply chain disruptions and as our customers, but there are number one.
Objective is to ensure that product is available for their patients.
And you know.
So as they solve for that.
There is.
Lesser of a pricing decline and the pricing erosion on base products than we've seen in the past.
Alright, that's encouraging and then just lastly on the generics business are you able to comp.
Comment on that.
I guess concentration of your portfolio I think historically you've had a pretty.
Pretty well diversified portfolio, if not ignore messages is spread pretty well can you talk about how that's changed this year with some of these benefits are there any one two or a handful of products that are <unk>.
Have driven outside outsized gains and whats maybe the largest single.
Or a handful of.
Revenue percentage.
In your portfolio now.
Yeah, I think that.
The diversification.
Litigation of our product portfolio across the generics business persist.
We.
So we have.
Multiple products in the generics business that has seen benefits from the supply chain disruptions and not one as you know.
So there are different scales of it but there are multiple products that have seen the benefit.
And.
Let Steve sort of jump in with it or is there a specific product that is I don't think so that as you know.
Disproportionately large afar.
<unk> of our overall generic business I think it's still you know.
Top 10%, but Steve you can just clarify.
That's that's correct.
And or on.
On the generic side of the portfolio.
The company.
Has this throughout the years rates driven to diversify.
The generics and at this moment in time I would say, we have quite a diverse portfolio and and no single product.
Taking into the lion's share of the generics portfolio.
Alright, and just lastly, the rare disease business has been outperforming as well I don't Wanna all they focused engine Harris.
Can you talk about.
The investments there I think once upon a time you told US you expected this year to have approximately 10%.
And year over year direct spend on that business.
Is it safe to assume that you have been investing more behind that than originally planned because of outperformance and is that necessary to support the demand or are you actually investing more to drive more demand.
Now and going forward.
Okay. Thank you Oren no I think that our.
Uh huh.
We have invested from an SG&A perspective in line with.
The numbers that you mentioned, which is 10% year on year over year increase.
And Oh.
Alright, thank you.
Congrats on another impressive.
Thank you Lauren.
Thank you.
At this time as we have no question standing by I will turn the conference back over to Nick <unk> for any additional or closing comments.
Thank you everyone for joining our call. This morning, we believe that our efforts during 2023 have created a strong foundation.
The foundation for continued success and fulfilling our purpose of serving patients.
Improving lives.
We look forward to updating you on our progress.
We appreciate your time and interest in Eni.
Thank you.
Ladies and gentlemen that does conclude today's conference. Thank you for your participation you may disconnect at this time.
[music].
Yes.
Uh huh.
Yeah.
Yeah.
[music].
Yeah.
Yeah.
Yeah.
[music].